Vendor Intelligence Report: Yimei

Executive summary

Yimei now reads as a rebrand-and-quality-dispersion file, not a simple vendor verdict. Across 109 Finnrick lab tests, Yimei posts an 84% overall pass rate: 92 passes and 17 failures. The record is uneven: GHK-Cu is the cleanest lane, Ipamorelin also tests comparatively well, Retatrutide is pass-majority but not clean, and TB-500 is the clearest weak signal. Ratings also contract under stricter Finnrick grading, so the public pass majority should not be read as tight dose control.

The identity work matters because many buyers will now meet Yimei through Peptaura and the Pepturion brand. Marketplace records document the Yimei-to-Pepturion bridge, while Pepturion’s own captured pages present a UK-based supplier claim without the ordinary UK legal identifiers. The full file follows a dissolved Yimei-named UK company, nominee-style secretary records, a Hong Kong WhatsApp contact, and China-side B2B supplier listings that point to Handan rather than a visible UK operating base.

Pepturion’s Retatrutide page displays a Janoshik COA, but the report treats it as a single-sample artifact rather than a distribution-wide control. Payment options recorded in the field run are UK bank transfer and cryptocurrency, limiting buyer recourse; the promotion scan also captured Yimei/Peptaura discount-code posts without clear disclosure. The practical read is product-specific: stronger Yimei lanes may be reasonable only with fresh batch verification, while weaker lines and unverifiable marketplace fulfillment deserve a higher bar or a different source.

Inside the full report:

• Per-product pass/fail rates, spark-grid trajectories, and methodology-divergence charts for all 8 tested products
• Screenshots documenting the Peptaura/PeptideStack Yimei-to-Pepturion rebrand bridge
• Companies House captures for the dissolved UK Yimei entity, officers, PSC, and secretarial chain
• Echemi, xchemi, EC21, and DIYTrade supplier-listing evidence tied to the Handan address
• Pepturion website, legal-notice, contact, payment, and Retatrutide COA analysis
• Promotion-network scan covering X referral links and Yimei-specific discount-code posts

Risk assessment

• Product-specific quality risk for weak peptides — high: TB-500 (42.62%), CJC-1295 (49.73%), Tesamorelin (56.64%), and BPC-157 (63.4%) are materially weaker than Yimei’s better-performing GHK-Cu and Ipamorelin lines.
• Retatrutide consistency and COA-reliance risk — medium: Retatrutide is pass-majority but not clean: 50 tests, 42 pass/8 fail, 83.5%, while Pepturion markets a single Janoshik COA.
• Misrepresented UK-base and corporate-recourse risk — high: Pepturion claims a UK base, but no UK Pepturion registration surfaced; the old YIMEI INTERNATIONAL company is dissolved and records point to Handan, China.
• Brand-continuity and marketplace-authenticity risk — medium: The Yimei-to-Pepturion rebrand is documented by Peptaura/PeptideStack, but the seller does not publish an entity bridge, official-channel list, or anti-counterfeit controls.
• Payment-recourse risk — medium: Pepturion FAQ lists UK bank transfer and cryptocurrency, leaving buyers without card or PayPal chargeback protection.
• Undisclosed Peptaura/Yimei promotion risk — medium: The scan found Yimei-specific and Peptaura referral-code promotion without clear disclosure, including Yimei Reta code Zeus and Peptaura code BLAZE posts.